Business Management Articles

ASCO Calls for Drug Pricing Reforms

As rumors circulate in Washington, DC, ASCO has called for efforts to reach a consensus on drug value to ensure affordability and access for patients and spur manufacturers to work harder on bringing innovative medicines to market.
ODAC Votes to Recommend Approval for Trastuzumab Biosimilar MYL-1401O
The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to recommend approval to MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals.
ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215
The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.
ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL
Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.
FDA Grants Full Approval to Blinatumomab for B-cell Precursor ALL
The FDA has granted a full approval to blinatumomab (Blincyto) as a treatment for adults and children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, regardless of Philadelphia chromosome status.
ODAC Recommends Approval of Gemtuzumab Ozogamicin for Newly-Diagnosed AML
The FDA’s Oncologic Drugs Advisory Committee voted 6-1 in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.
Genentech Survey: Many Practices Unprepared for USP <800>
In 2016, just a quarter of oncology practices considered themselves prepared for upcoming US Pharmacopeia (USP) <800> standards on hazardous drug management, according to the 2017 Genentech Oncology Trend Report.
Time to Focus on Succession Planning as Retirements Loom
Joliet Oncology-Hematology decided to create new governance and compensation structures and eventually elected a new president.
Whether the practice is large, with a boutique staffed by a full-time employee, or small, with an unmanned rack in the waiting room, it isn’t uncommon for a clinic to try selling nonmedical products to patients.
About 5 years ago, Texas Oncology moved to improve accountability and pathways compliance by introducing a pay incentive that put 2% to 3% of a physician’s pay at risk.
Publication Bottom Border
Border Publication